Cardiovascular disease: risk assessment and reduction, including lipid modification

Supporting evidence

• Other supporting evidence

• Methods for evidence review D (PDF 331 KB)

  Published:

  14 December 2023

• Methods for evidence reviews A to C (PDF 524 KB)

  Published:

  24 May 2023

• Evidence review

• Evidence reviews

• D: Escalation of lipid-lowering treatment for secondary prevention of CVD (PDF 3.48 MB)

  Published:

  14 December 2023

• A: CVD risk assessment tools: primary prevention (PDF 2.97 MB)

  Published:

  24 May 2023

• B: Dietary cholesterol strategies (PDF 660 KB)

  Published:

  24 May 2023

• C: Statins: efficacy and adverse effects (PDF 3.66 MB)

  Published:

  24 May 2023

• Economic analysis

• Cost-utility analysis for escalation of lipid-lowering treatment for secondary prevention of CVD (PDF 2.27 MB)

  Published:

  14 December 2023

• Network meta-analysis of changes in LDL cholesterol and non-HDL cholesterol as a result of escalation of lipid-lowering treatment for secondary prevention of CVD (PDF 623 KB)

  Published:

  14 December 2023

• Surveillance report

• 2023 exceptional surveillance of cardiovascular disease: risk assessment and reduction, including lipid modification (NICE guideline CG181)

• Appendix A: Stakeholder consultation comments table (PDF 702 KB)

  Published:

  19 January 2023

• Surveillance report 2018 – Cardiovascular disease: risk assessment and reduction, including lipid modification (2014) NICE guideline CG181

• Appendix A: Evidence summaries (PDF 952 KB)

  Published:

  25 January 2018

• Appendix B: Stakeholders comments (PDF 505 KB)

  Published:

  25 January 2018

• Full guidance

• Full guideline - July 2014 (PDF 4.39 MB)

  Published:

  27 September 2016

• Appendices (PDF 9.32 MB)

  Published:

  27 September 2016